Pipeline Screening
Run an automated Quick Screen on each company in your pipeline: six independent signals per company, each linked to its source records, with no composite score and no ranking verdict. $5,000 per company; funds that screen regularly can license Vantage instead.
The Challenge
You see far more companies than you can diligence in depth.
Reading even ten companies in depth takes significant team time, and good deals move while the work is still under way.
Different team members read risk differently. The same six signals on every company give the team a consistent starting point.
Regulatory, clinical and technical questions can surface late in diligence, after time has already gone into the wrong opportunities.
Dedicated clinical and technical staff are expensive. A consistent first read helps decide where that expertise is worth spending.
How It Works
Four steps from your list to a shortlist you choose
The companies you want screened, with a complete intake for each.
Each company’s public record is read across six signals: regulatory posture, clinical evidence, IP, reimbursement, team and competitive position.
Each signal is reported on its own and linked to its source records. No composite score, no ranking and no go/no-go call.
For the companies you shortlist, commission a Diligence Report reviewed by a physician and a biomedical engineer. The Quick Screen fee credits in full toward it.
Pricing
Pay per Quick Screen, or license Vantage if you screen regularly
Quick Screen
$5,000
per company
An automated first read on one company
Fund License
$95,000
per year
For funds with steady deal flow
Platform License
$160,000
per year
For firms screening across a full portfolio
Enterprise
Priced to portfolio
annual
For high-volume funds and PE portfolios
Universities and incubators: annual TTO and Incubator programs run $45–75K a year. See TTOs and incubators.
Per Company
Regulatory posture, clinical evidence, IP, reimbursement, team and competitive position, each reported on its own.
Each signal is linked to the FDA, SEC, ClinicalTrials.gov, USPTO, CMS or other public records it rests on.
Where the public record says little, the screen says so rather than filling the gap.
No composite score, no ranking and no go/no-go call. You decide what the signals mean for your pipeline.
Investment Teams
How It Differs
Quick Screens are automated. Diligence Reports on your shortlist are reviewed by Arvind Ravinutala, MD, and Aswini Ravinutala, BME.
Each signal links to the public records behind it, so you can check it yourself.
Every company is read on the same six signals, so the comparison across your pipeline is like for like.
Each Quick Screen is delivered within 24 hours of a complete intake.
The Team
Arvind Ravinutala, MD, practicing physician and P&T Committee Chair, leads clinical and regulatory review on full reports.
Aswini Ravinutala, BME, biomedical engineer with 10+ years in medical devices and R&D Manager at Spiro Medical, leads technical, manufacturing and quality review on full reports.
Signals are linked to public records from 34 sources, including FDA, SEC, ClinicalTrials.gov, NIH, CMS and USPTO.
Start with a Quick Screen on one company, or talk to us about a fund license.